Omega Funds

Omega Funds is a venture capital investment firm established in 2004 and located in Boston, Massachusetts. The firm specializes in investing in various sectors, including life sciences, digital health, immunology, rare diseases, precision medicine, oncology, cybersecurity, and software as a service. As a Registered Investment Adviser, Omega Funds focuses on identifying and supporting innovative companies within these fields to drive advancements and improve outcomes in healthcare and technology.

Hugo Beekman

Principal

Francesco Draetta

Managing Director

Paulina Hill

Biotech investor

Claudio Nessi

Managing Director

Michael Powell

Executive Partner

Otello Stampacchia

Founder

Saoussen Ben Halima Ph.D

Senior Associate, Investment

Mene Pangalos

Partner

146 past transactions

Callio Therapeutics

Series A in 2025
Callio Therapeutics focuses on developing next-generation, multi-payload antibody-drug conjugates to maximize therapeutic benefits.

Alleviant Medical

Venture Round in 2025
Alleviant Medical, Inc. is a medical device company focused on developing therapies for congestive heart failure. Founded in 2017 and headquartered in Austin, Texas, the company offers a proprietary transcatheter device designed to provide minimally invasive treatment for heart failure. This innovative technology aims to relieve pressure buildup in the left atrium, which can lead to organ failures, thereby alleviating symptoms of heart failure. By improving patients' quality of life and reducing hospital admissions due to heart failure exacerbations, Alleviant Medical addresses the needs of over 6 million Americans suffering from this condition.

Windward Bio

Series A in 2025
Windward Bio is a clinical-stage drug development company focused on improving outcomes for individuals with advanced immunological diseases, particularly severe respiratory conditions. The company is advancing a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP) into phase 2 development while creating innovative bispecific programs for various immunological disorders. Led by a team of biopharmaceutical executives, Windward Bio aims to address significant unmet medical needs in this field.

Aviceda Therapeutics

Series C in 2025
Aviceda Therapeutics is a late-stage, pre-clinical biotechnology company focused on developing innovative treatments for glyco-immune diseases. By leveraging glycobiology and a proprietary cell-based high-throughput screening platform, the company aims to create next-generation immunomodulators that target the innate immune system and address chronic non-resolving inflammation. Aviceda's product pipeline includes candidates for a variety of conditions, such as eye diseases, fibrosis, neurology, and oncology. Key products under development include AVD-104, AVD-302, and AVD-401 for dry eye, diabetic retinopathy, and retinoblastoma, as well as AVD-601, AVD-701, and AVD-801 targeting oncology, neurology, and fibrosis. Through its advanced technologies and biological insights, Aviceda seeks to provide breakthrough glycol-therapeutics that improve patient outcomes.

Ikena Oncology

Post in 2024
Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.

nChroma Bio

Venture Round in 2024
nChroma Bio's integrated product engine allows for safe, accurate, and targeted in vivo administration, addressing major shortcomings of current genetic medicine techniques.

Beta Bionics

Series E in 2024
Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

XII Medical

Series B in 2024
XII Medical is a medical device developer focused on creating innovative solutions for obstructive sleep apnea. The company has developed a minimally invasive outpatient technology that includes an implantable neurostimulation device designed to alleviate the condition. This device works by preventing the muscles in the throat from relaxing during sleep, thereby avoiding airway blockage and enabling patients to enhance oropharyngeal airflow. Through its advancements in sleep apnea treatment, XII Medical aims to improve patient outcomes and provide a proactive approach to managing this common sleep disorder.

Kestra Medical Technologies

Private Equity Round in 2024
Kestra Medical Technologies, Inc. specializes in the development and manufacturing of wearable medical devices designed for monitoring and managing acute medical conditions. Founded in 2014 and based in Kirkland, Washington, the company offers solutions that collect, communicate, and store patient performance data, enabling both real-time and retrospective analysis. Among its products are wearable cardioverter defibrillators, which aim to prevent sudden cardiac death and facilitate cardiac recovery in at-risk patients. Kestra Medical Technologies focuses on creating intuitive and mobile diagnostic and therapeutic technologies that support healthcare providers and enhance patient care.

Catalym

Series D in 2024
CatalYm GmbH, founded in 2016 and based in Munich, Germany, is a biotechnology company focused on developing innovative immunotherapies for cancer patients. The company has identified GDF-15 as a key regulator of the immune system within the tumor microenvironment. By neutralizing GDF-15, CatalYm aims to enhance the immune response against solid tumors, potentially leading to meaningful clinical outcomes. Its CTL-002 program is designed to demonstrate clinical proof-of-concept across multiple solid tumor indications, offering the prospect of expanding treatment options for cancer patients. Through its approach, CatalYm seeks to transform the tumor microenvironment, making tumors more accessible to the immune system and improving both survival rates and quality of life for patients.

Scorpion Therapeutics

Series C in 2024
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

BridgeBio Oncology Therapeutics

Venture Round in 2024
BridgeBio Oncology Therapeutics operates as a biopharmaceutical company.

Endeavor BioMedicines

Series C in 2024
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Alumis

Series C in 2024
Alumis is a clinical-stage biopharmaceutical company dedicated to developing precision medicines for autoimmune disorders. By leveraging a proprietary data analytics platform and biological insights, Alumis aims to transform the treatment landscape for patients suffering from these conditions. The company focuses on identifying and advancing therapeutics based on genetically validated targets, which enables the creation of targeted therapies that significantly improve patient outcomes. With a team of experts experienced in drug discovery and immunology, Alumis seeks to replace broad immunosuppression with more effective, targeted treatment options, ultimately enhancing the quality of life for individuals affected by autoimmune diseases.

ARTBIO

Series A in 2023
ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

Eyebiotech

Series A in 2023
Eyebiotech is a vision treatment company that develops products to preserve, repair, and improve eyesight. The firm guards against sight-threatening eye disorders and developed the first anti-vascular endothelial growth factor medication for patients with age-related macular degeneration, allowing those with eye ailments to regain their eyesight.

Beta Bionics

Series D in 2023
Beta Bionics is a biotechnology company focused on developing an integrated bionic pancreas system known as the iLet. This innovative device aims to alleviate the challenges and costs associated with diabetes care by providing a dual-chamber infusion pump that delivers insulin and glucagon with precision. The iLet autonomously calculates and administers the necessary doses, enabling patients to effectively manage their blood sugar levels. The system has received breakthrough designation for all its configurations, including insulin-only, glucagon-only, and bihormonal options, and is compatible with Zealand Pharma’s dasiglucagon, a glucagon analogue known for its stability in a ready-to-use aqueous solution. Through this technology, Beta Bionics seeks to improve the quality of life for individuals living with diabetes.

ARTBIO

Seed Round in 2023
ARTBIO is a clinical-stage biotechnology company focused on developing innovative alpha radioligand therapies for cancer treatment. By utilizing radioligand therapy, ARTBIO aims to deliver alpha or beta emitters that target and disrupt cancer cell DNA, offering a new approach to oncology. The company is committed to creating a supportive ecosystem that enhances the efficacy of its therapeutics, thereby enabling medical professionals to utilize novel mechanisms in cancer care. Through its advancements, ARTBIO seeks to transform the landscape of cancer treatment and improve patient outcomes.

Upstream Bio

Series B in 2023
Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

Chroma Medicine

Series B in 2023
Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

SoniVie

Series C in 2023
SoniVie is engaged in the development of a medical device aimed at treating pulmonary hypertension through advanced denervation techniques. The company’s device involves a catheter that is inserted into the pulmonary artery during a minimally invasive procedure. This device selectively targets and damages the nerves linked to the disease without affecting the vessel walls or surrounding tissues, allowing physicians to effectively address the condition.

NRG Therapeutics

Series A in 2022
NRG Therapeutics is a drug discovery company established in 2018 that specializes in developing therapeutic approaches aimed at restoring mitochondrial function to address neurodegenerative diseases, including Parkinson’s disease, Alzheimer’s disease, and motor neuron disease. The company focuses on creating novel medicines that preserve mitochondrial function and halt disease progression. With a team experienced in neuroscience drug discovery, NRG Therapeutics is initially concentrating on the discovery and development of brain-penetrant inhibitors of the mitochondrial permeability transition pore specifically for Parkinson’s disease. This strategic focus is intended to empower physicians with effective treatment options for patients suffering from chronic neurodegenerative disorders.

Photys Therapeutics

Series A in 2022
Photys Therapeutics is a biopharmaceutical company focused on developing bifunctional small molecules that provide precise control over protein post-translational modifications. This innovative platform allows for the restoration of protein function, repair of cellular signaling pathways, and enhancement of the body's natural disease-fighting abilities. Co-founded by prominent chemist Amit Choudhary from the Broad Institute and the Longwood Fund, Photys is supported by a scientific advisory board that includes renowned experts from institutions such as MIT, Salk Institute, and Berkeley. The company's unique approach aims to advance therapeutic options in the healthcare industry, particularly by targeting kinases and potentially phosphatases, to address various diseases effectively.

etherna immunotherapies

Series B in 2022
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

Upstream Bio

Series A in 2022
Upstream Bio is a clinical-stage biotechnology company dedicated to developing antibody therapies for inflammatory diseases, particularly severe asthma and other respiratory disorders. The company's lead candidate, verekitug, is a monoclonal antibody that acts as an antagonist to the Thymic Stromal Lymphopoietin (TSLP) receptor. TSLP is a key cytokine that drives inflammatory responses and is strategically positioned upstream of various signaling pathways influencing immune cells. Upstream Bio aims to address unmet medical needs in the treatment of severe respiratory conditions by leveraging this validated target to create effective therapies.

CDR-Life

Series A in 2022
CDR-Life is a Zurich-based biotech company specializing in the development of innovative therapeutic antibody fragments, with particular emphasis on immuno-oncology and ophthalmology. Operating from the Bio-Technopark in Schlieren-Zurich, the company focuses on creating tumor-selective immunotherapies. Its technology is designed to produce MHC-specific antibodies that target tumor-specific intracellular antigens, thereby enabling healthcare providers to deliver more precise and effective treatments for cancer patients.

Aerium Therapeutics

Series A in 2022
Aerium Therapeutics focuses on the discovery and development of novel monoclonal antibodies and antiviral treatments aimed at combating SARS-CoV-2 variants. The company is dedicated to creating a pipeline of biologics and small molecule antivirals, specifically designed to address pandemic and epidemic threats. Its fully integrated discovery platform utilizes a wide network of international collaborations and established research infrastructures. This approach enables the development of targeted antigens for both the treatment and prevention of COVID-19, as well as emerging variants of the virus.

Endeavor BioMedicines

Series B in 2022
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Chroma Medicine

Series A in 2021
Chroma Medicine is a genomic medicine company founded in 2021 and based in Cambridge, Massachusetts, specializing in epigenetic editing. The company is pioneering a new class of genomic therapies aimed at revolutionizing the treatment of genetically driven diseases. By utilizing epigenetics, which is the natural mechanism for gene regulation, Chroma Medicine develops programmable epigenetic editors that target specific genes and modulate chromatin conformation. This innovative approach enables healthcare providers to achieve precise control of gene expression, offering a promising therapeutic option for conditions linked to genetic anomalies.

Rectify Pharmaceuticals

Series A in 2021
Rectify Pharmaceuticals is focused on creating disease-modifying precision therapies aimed at addressing the root causes of serious genetic diseases. The company specializes in developing positive functional modulators (PFMs) that restore the function of ABC transporters, which are critical for cellular processes. By targeting these underlying mechanisms, Rectify aims to provide innovative treatment solutions that improve the health outcomes of patients suffering from various genetic conditions. Their research and development efforts encompass multiple therapeutic areas, reflecting a commitment to advancing precision medicine in the field of genetic disorders.

CinCor Pharma

Series B in 2021
CinCor Pharma, Inc. is a clinical-stage biopharmaceutical company based in Cincinnati, Ohio, established in 2018. The company is dedicated to developing clinical candidates targeting cardiovascular, metabolic, and kidney diseases. Its primary focus is on CIN-107, an aldosterone synthase inhibitor aimed at treating resistant hypertension and primary aldosteronism. CinCor Pharma's mission is to advance its promising clinical candidates toward marketing approval, emphasizing the development of innovative therapies for patients suffering from cardio-renal conditions.

Thankful

Series A in 2021
Thankful, Inc. is a company based in Los Angeles, California, that develops an artificial intelligence platform aimed at enhancing online customer service. The platform is designed to address and deflect a significant portion of repetitive customer inquiries, allowing customer care agents to focus on more complex issues. Its features include automated responses to questions, information gathering, ticket routing, and advanced script management. By improving the efficiency of customer service operations, Thankful's software helps eCommerce businesses increase customer satisfaction and reduce operational costs. The platform supports various written communication channels, providing customers with flexibility in how they engage with support services.

Alpine Immune Sciences

Post in 2021
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Vanqua Bio

Series B in 2021
Vanqua Bio is a biotechnology company dedicated to discovering and developing innovative medicines for patients suffering from neurodegenerative diseases. The company leverages a technology platform that incorporates human genetics and patient-derived neuronal cells to identify and validate new disease pathways linked to lysosomal dysfunction and the inappropriate activation of the innate immune system. Vanqua Bio focuses on creating small-molecule activators of glucocerebrosidase and advancing programs that target the innate immune system, with the aim of addressing the progression of various neurological disorders. Through its efforts, the company seeks to provide healthcare professionals with transformative treatment options for patients facing these challenging conditions.

Lexeo Therapeutics

Series B in 2021
Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Artios Pharma

Series C in 2021
Artios Pharma Limited is a biotechnology company based in Cambridge, United Kingdom, that specializes in developing innovative cancer treatments targeting DNA damage response (DDR) pathways. Founded in 2015, the company is dedicated to creating first-in-class therapies aimed at selectively killing cancer cells. Artios's product pipeline features several promising programs, including a focus on DNA polymerase theta (Polθ), which plays a crucial role in DNA repair processes. Additionally, the company is advancing an in-licensed program that targets a newly identified protein linked to DDR and is developing a novel treatment aimed at DNA nucleases involved in these pathways. Artios collaborates with Cancer Research Technology and prominent DNA repair researchers globally to enhance its research and development efforts.

Synthekine

Series B in 2021
Synthekine Inc. is a biotechnology company focused on developing innovative cytokine therapies and immunotherapies for cancer and autoimmune disorders. Established in 2018 and located in Menlo Park, California, the company employs advanced platforms such as engineered partial agonists and orthogonal cell therapies. Its Synthekine Platform utilizes surrogate agonists instead of traditional mutant cytokines, allowing for the creation of therapeutics that enhance efficacy while minimizing side effects. The product pipeline includes STK-009, an orthogonal ligand, and SYNCAR-001, a CAR-T therapy targeting CD-19, along with STK-012, which consists of partial agonists of IL-2. Synthekine aims to revolutionize treatment paradigms by harnessing the principles of cytokine partial agonism and immunological specificity, leading to novel immunotherapies that improve patient outcomes.

Invivyd

Series C in 2021
Invivyd is a biopharmaceutical company committed to developing antibody-based therapies aimed at providing protection against serious viral infectious diseases. The company focuses on creating solutions that go beyond naturally occurring immunity, particularly in response to viral threats with pandemic potential, starting with SARS-CoV-2. Its product pipeline includes ADG20, which is designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody engineered for enhanced potency and broad coverage. By prioritizing rapid and enduring therapeutic options, Invivyd aims to safeguard vulnerable populations from the severe impacts of circulating viral infections.

Theseus Pharmaceuticals

Series B in 2021
Theseus Pharmaceuticals is a biopharmaceutical company dedicated to enhancing the lives of cancer patients by discovering, developing, and commercializing innovative targeted therapies. The company's primary focus is on addressing drug resistance mutations in key driver oncogenes, which are mutated genes that contribute to the progression of cancer. By leveraging advanced technologies, Theseus Pharmaceuticals aims to create transformative treatments that can overcome challenges associated with existing therapies, thereby improving patient outcomes in oncology.

Icosavax

Series B in 2021
Icosavax, Inc. is a biotechnology company based in Seattle, Washington, founded in 2017. The company specializes in developing vaccines using its innovative virus-like particle (VLP) technology platform, which allows for the multivalent display of complex viral antigens. This technology aims to provide broad and durable protection against various infectious diseases, with an initial focus on life-threatening respiratory illnesses. Icosavax's pipeline includes vaccine candidates targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and SARS-CoV-2. The company is dedicated to advancing its VLP technology to discover, develop, and ultimately commercialize effective vaccines against these infectious diseases.

Amunix

Series B in 2021
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Scorpion Therapeutics

Series B in 2021
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Lexeo Therapeutics

Series A in 2021
Lexeo Therapeutics is a biotechnology company specializing in adeno-associated virus (AAV)-mediated therapies for both rare and common diseases caused by single gene mutations. Headquartered in New York, the company maintains an integrated pipeline developed in collaboration with Weill Cornell Medicine's Department of Genetic Medicine. Lexeo focuses on advancing its clinical programs towards commercialization while continuing to research new therapies for various patient populations and unmet medical needs.

Endeavor BioMedicines

Series A in 2021
Endeavor BioMedicines is a clinical-stage company based in Solana Beach, California, that focuses on developing innovative treatments for pulmonary fibrosis, particularly idiopathic pulmonary fibrosis (IPF). Founded in 2018, the company is working on a small-molecule inhibitor designed to target the underlying causes of this progressive lung disease. The treatment aims to not only halt the progression of IPF but also has the potential to reverse its effects, offering healthcare professionals a new avenue for precision treatments in managing terminal conditions. Endeavor BioMedicines strives to improve patient outcomes and enhance quality of life for those affected by this challenging illness.

Ikena Oncology

Series B in 2021
Ikena Oncology is a biotechnology company based in Boston, Massachusetts, focused on developing innovative therapies for cancer treatment. The company specializes in biomarker-driven and precision therapies that target specific mechanisms involved in cancer growth, spread, and resistance. Its product pipeline includes several candidates such as IK-007, an EP4 receptor antagonist; IK-175, an AHR antagonist; and IK-930, an oral small-molecule inhibitor of the TEAD transcription factor in the Hippo signaling pathway. Additionally, Ikena is exploring a kynurenine-degrading enzyme with IK-412 and other discovery-stage programs targeting various oncogenic pathways. Established in 2016, Ikena Oncology aims to address unmet medical needs through a combination of chemistry, translational science, and patient-centered drug development.

Syros Pharmaceuticals

Post in 2020
Syros Pharmaceuticals is a life sciences company that is focused on treating disease by mapping gene regulatory circuits and modulating the factors that regulate gene expression. Syros has pioneered world-leading gene control research and drug discovery capabilities with a proven ability to integrate disease biology and genomic data--a proficiency that is not well represented in pharmaceutical R&D. Central to the Syros approach is a proprietary platform of carefully integrated assay technologies, bioinformatics, and biologic insights developed by members of Syros' senior leadership. While this scientific approach has applications in many therapeutic areas, Syros has demonstrated success initially in oncology, where it may help address numerous unmet medical needs.

Imago BioSciences

Series C in 2020
Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Invivyd

Series B in 2020
Invivyd is a biopharmaceutical company committed to developing antibody-based therapies aimed at providing protection against serious viral infectious diseases. The company focuses on creating solutions that go beyond naturally occurring immunity, particularly in response to viral threats with pandemic potential, starting with SARS-CoV-2. Its product pipeline includes ADG20, which is designed for the treatment and prevention of COVID-19, and VYD222, a monoclonal antibody engineered for enhanced potency and broad coverage. By prioritizing rapid and enduring therapeutic options, Invivyd aims to safeguard vulnerable populations from the severe impacts of circulating viral infections.

Scorpion Therapeutics

Series A in 2020
Scorpion Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on developing next-generation precision oncology technologies for cancer treatment. Founded in 2020, the company specializes in creating targeted small-molecule drugs that interact with validated cancer targets. Its research encompasses therapies aimed at known oncogenes, previously undruggable cancer targets, and novel targets. By integrating technologies across target discovery, medicinal chemistry, and translational medicine, Scorpion Therapeutics aims to advance a comprehensive pipeline of optimized compounds. The company's goal is to expand the reach of precision medicine, enabling healthcare professionals to offer innovative treatments to a broader range of cancer patients.

Nuvation Bio

Post in 2020
Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Chord Therapeutics

Series A in 2020
Chord Therapeutics is a biotechnology company based in Geneva, Switzerland, focused on developing treatments for rare, life-threatening neurological diseases. Established in 2014, the company specializes in repurposing small molecule drugs to create effective therapies. Its lead product, CRD1, is being advanced under orphan drug designation for conditions such as neuromyelitis optica spectrum disorders and myasthenia gravis. Chord Therapeutics aims to provide solutions that significantly improve the lives of patients affected by these severely disabling illnesses.

Kronos Bio

Private Equity Round in 2020
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Alpine Immune Sciences

Funding Round in 2020
Alpine Immune Sciences, Inc. is a clinical-stage biopharmaceutical company based in Seattle, Washington, that specializes in the discovery and development of protein-based immunotherapies aimed at treating cancer, autoimmune, and inflammatory disorders. The company leverages a proprietary scientific platform to transform native immune system proteins into innovative therapeutic candidates. Its leading programs include ALPN-101, a dual antagonist targeting the inducible T cell costimulator and CD28 pathways, designed for autoimmune and inflammatory conditions, and ALPN-303, a dual antagonist of the B cell activating factor and proliferation-inducing ligand, which is vital for B cell activation and survival. Additionally, Alpine Immune Sciences has established a collaboration with Kite Pharma to explore immunotherapies targeting the immune synapse for cancer treatment.

Sana Biotechnology

Series A in 2020
Sana Biotechnology, Inc. is a biotechnology company focused on developing engineered cells as therapies to treat a wide range of diseases. Established in 2018 and headquartered in Seattle, Washington, with additional offices in South San Francisco and Cambridge, the company utilizes advanced scientific techniques to reprogram cells or replace damaged cells and tissues. This innovative approach aims to create a new class of medicines that address unmet treatment needs across various therapeutic areas, including oncology, diabetes, autoimmune disorders, and central nervous system conditions. Sana's pipeline includes several product candidates designed to provide meaningful medical solutions and transform disease treatment methodologies.

etherna immunotherapies

Series B in 2020
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

Checkmate Pharmaceuticals

Series C in 2020
Checkmate Pharmaceuticals, Inc. is a clinical-stage biotechnology company based in Cambridge, Massachusetts, focused on developing novel immunotherapies for cancer treatment. The company specializes in CpG oligonucleotides, which are designed to stimulate an anti-tumor T-cell response while counteracting the mechanisms that tumors use to evade the immune response. Checkmate aims to enhance the effectiveness of existing immunotherapies and provide new treatment options for patients through its innovative approaches. Since its incorporation in 2015, Checkmate has established strategic partnerships with major pharmaceutical companies, including Merck KGaA and Pfizer, to advance its clinical programs and broaden the impact of its research in the field of cancer immunotherapy.

Atea Pharmaceuticals

Series D in 2020
Atea Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, that focuses on discovering and developing antiviral therapies for severe viral infections. The company's lead candidate, AT-527, is an antiviral agent currently undergoing phase 3 clinical trials for the treatment of COVID-19, caused by SARS-CoV-2. Additionally, Atea is developing several other product candidates, including AT-787, which is in phase 2 trials for hepatitis C, and AT-752 for dengue. Other candidates, such as AT-889 and AT-934, are also in phase 2 clinical trials targeting respiratory syncytial virus. Established in 2014, Atea Pharmaceuticals aims to improve treatment options for patients suffering from serious viral infections.

FoRx Therapeutics

Seed Round in 2020
FoRx Therapeutics AG is a biotechnology company based in Basel, Switzerland, founded in 2019. The company specializes in the development of innovative therapeutics for cancer treatment, specifically targeting key molecular pathways involved in DNA replication stress. By focusing on these novel pathways, FoRx Therapeutics aims to create first-in-class compounds that offer a new approach to targeted anticancer therapies. Through its research and development efforts, the company seeks to provide effective solutions in the fight against cancer.

Amunix

Series A in 2020
Amunix Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to discovering and developing innovative protein and peptide therapeutics aimed at treating cancer. The company employs several proprietary platforms, including XTEN for extending drug half-life, XPAT for analyzing protease activity in the tumor microenvironment, and ProTIA, which focuses on immuno-oncology therapeutics. Amunix's product pipeline includes prodrugs and transformative T-cell engagers designed to activate the immune system against solid tumors. The company collaborates with various academic, biotechnology, and pharmaceutical sectors, maintaining strategic partnerships with organizations such as Janssen and Biogen-Idec. Founded in 2006 and headquartered in Mountain View, California, Amunix strives to deliver breakthroughs that can harness the immune system to combat cancer more effectively.

Spruce Biosciences

Series B in 2020
Spruce Biosciences, Inc. is a biopharmaceutical company dedicated to developing and commercializing innovative therapies for rare endocrine disorders, particularly those affecting the hypothalamic-pituitary-adrenal axis. Founded in 2014 and headquartered in Daly City, California, the company is advancing its lead product candidate, tildacerfont, which is currently undergoing Phase IIb clinical trials for adult patients and Phase II clinical trials for children with classic congenital adrenal hyperplasia (CAH). Tildacerfont is positioned as a potential first non-steroidal therapy that aims to improve disease control and reduce the reliance on steroids for patients with CAH. Additionally, Spruce is exploring the use of tildacerfont for women with polycystic ovary syndrome. The company has also entered into a licensing agreement with Eli Lilly and Company to research and develop compounds for various pharmaceutical applications.

Anaconda Biomed

Series B in 2019
Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.

IFM Therapeutics

Venture Round in 2019
IFM Therapeutics specializes in developing small molecule medicines that target the innate immune system to address complex challenges in treating inflammatory and autoimmune disorders, as well as cancer. The company collaborates with academic partners to leverage expertise in innate immunity alongside experienced drug discovery professionals. Its subsidiary, IFM Due, focuses on discovering and developing antagonists of the cGAS/STING pathway, aiming to treat conditions such as inflammation, neuroinflammation, autoimmunity, and cancer. Additionally, IFM Discovery, a newly established incubator within the company, is engaged in advancing a portfolio of genetically validated targets for next-generation therapies addressing inflammation, neuroinflammation, autoimmunity, and fibrosis. Through these initiatives, IFM Therapeutics seeks to enhance immune response and improve the quality of life for patients facing serious health challenges.

Nuvation Bio

Series A in 2019
Nuvation Bio Inc. is a biopharmaceutical company dedicated to addressing unmet needs in oncology through the development of novel therapies for challenging cancers. Founded in 2018 and headquartered in New York, with an additional office in San Francisco, Nuvation Bio focuses on treating patients whose conditions have not responded to conventional treatments. The company's leading clinical-stage candidate, NUV-868, is a BD2-selective oral small molecule BET inhibitor that targets the BRD4 protein, which plays a crucial role in regulating tumor growth and differentiation. In addition to NUV-868, Nuvation Bio is advancing a proprietary small molecule Drug-Drug Conjugate platform aimed at enhancing therapeutic efficacy. The company’s comprehensive portfolio includes multiple drug development candidates designed to meet the specific needs of cancer patients.

Arcutis Biotherapeutics

Series C in 2019
Arcutis Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company headquartered in Westlake Village, California, specializing in the development and commercialization of treatments for immune-mediated dermatological diseases. Founded in 2016, Arcutis is focused on addressing unmet medical needs in dermatology by leveraging advances in immunology and inflammation. Its lead product candidate, a topical cream formulation of roflumilast, is undergoing Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. Additionally, the company is developing other innovative therapies, including a topical foam formulation for seborrheic dermatitis and scalp psoriasis, a selective small molecule inhibitor for hand eczema, and a specialized formulation designed for alopecia areata. Arcutis aims to provide differentiated therapies that effectively tackle persistent treatment challenges in serious skin conditions.

Kronos Bio

Series A in 2019
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Arrakis Therapeutics

Series B in 2019
Arrakis Therapeutics, Inc. is a biopharmaceutical company focused on developing a proprietary platform for drug discovery that targets ribonucleic acid (RNA). The company aims to identify new RNA targets and create small-molecule drug candidates, primarily addressing cancer and other genetically validated diseases. Its innovative platform combines advanced RNA bioinformatics, structural tools, chemical biology, and medicinal chemistry, facilitating the development of RNA-targeted small molecules (rSMs). Additionally, Arrakis offers SHAPEware, a software tool designed to predict RNA secondary structures and potential ligand-binding sites. Founded in 2015, Arrakis Therapeutics is headquartered in Waltham, Massachusetts, and its work enables improved treatment options for various conditions, including neurological disorders and rare genetic diseases.

Prevail Therapeutics

Series B in 2019
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.

Imago BioSciences

Series B in 2019
Imago BioSciences is a clinical-stage biotechnology company based in Redwood City, California, that specializes in developing innovative medicines for hematologic diseases. Founded in 2012, the company focuses on therapeutics that target genetic and epigenetic factors, specifically through the inhibition of lysine-specific demethylase 1 (LSD1), an enzyme crucial in blood cell production. Imago BioSciences aims to address significant medical challenges associated with conditions such as leukemia, myelodysplastic syndrome, and other bone marrow disorders. Its lead product candidate, Bomedemstat, is an orally available small molecule designed to treat certain myeloproliferative neoplasms, with the goal of altering disease progression and improving the quality and longevity of patients' lives.

Beam Therapeutics

Series B in 2019
Beam Therapeutics Inc. is a biotechnology company based in Cambridge, Massachusetts, specializing in the development of precision genetic medicines utilizing its innovative base editing technology. Founded in 2017, the company aims to provide lifelong cures for patients suffering from serious diseases by targeting specific bases in the genome without inducing double-stranded breaks in DNA. Beam Therapeutics is actively developing therapies for a range of conditions, including sickle cell disease, beta-thalassemia, pediatric T-cell acute lymphoblastic leukemia, pediatric acute myeloid leukemia, alpha-1 antitrypsin deficiency, glycogen storage disorder type 1A, as well as ocular and central nervous system disorders. The company’s diverse pipeline includes several programs such as BEAM-101, BEAM-201, BEAM-301, BEAM-302, and ESCAPE, reflecting its commitment to advancing gene correction, gene modification, gene activation, gene silencing, and multiplex editing technologies.

Trevi Therapeutics

Series C in 2019
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Morphic Therapeutic

Series B in 2018
Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies aimed at treating serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer. The company specializes in creating small molecule inhibitors that target various integrins. By leveraging insights into integrin biology, Morphic Therapeutic is building a pipeline of innovative therapeutics designed to address a range of immunological, fibrotic, neoplastic, and vascular diseases, thereby offering potential new treatment options for patients with significant unmet medical needs.

First Wave Bio

Venture Round in 2018
First Wave Bio, Inc. is a clinical-stage biotechnology company based in Ann Arbor, Michigan, established in 2015. The company focuses on developing gut-targeted small molecules aimed at treating inflammatory bowel disease (IBD) and other serious conditions. First Wave Bio's innovative solutions include a gut-restricted small molecule that can be administered either orally or rectally, specifically designed to treat ulcerative colitis and other forms of IBD. This approach aims to provide patients with more accessible and cost-effective treatment options, addressing the critical need for effective and safe therapies in this therapeutic area.

Gossamer Bio

Series B in 2018
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that focuses on the discovery and development of innovative therapeutic products for unmet medical needs. Founded by former executives from Receptos, the company aims to leverage a strong in-licensing strategy and a team with extensive experience in immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising candidates: Seralutinib, which targets pulmonary arterial hypertension; GB004, aimed at treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; GB1275, designed for various oncology indications; and GB001, intended for moderate-to-severe eosinophilic asthma. Through these efforts, Gossamer Bio seeks to improve patient outcomes in critical therapeutic areas.

Andrew Alliance

Series C in 2018
Andrew Alliance S.A., founded in 2011 and based in Geneva, Switzerland, specializes in the development and commercialization of robotic solutions for the life sciences sector. The company offers a range of products designed to enhance laboratory efficiency and accuracy in liquid handling. Its key offerings include OneLab, a user-friendly graphical interface for liquid handling tasks; Andrew+, a robotic pipetting system utilizing conventional electronic pipettes; and Andrew, a portable robot that operates unattended manual pipettes. Additionally, Andrew Assistant is a software tool for designing and documenting biological protocols requiring precise liquid handling. By integrating advanced robotics, innovative hardware, and software algorithms, Andrew Alliance aims to transform laboratory workflows that currently rely on manual processes. The company sells its products directly and through a network of distributors in Switzerland and internationally. Andrew Alliance's operations are supported by strategic initiatives such as VentureKick and the EUREKA EUROSTARS program, ensuring the development of cutting-edge technology tailored to the needs of biologists and technicians.

Kronos Bio

Seed Round in 2018
Kronos Bio, Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing innovative cancer therapeutics. Founded in 2017 and headquartered in San Mateo, California, the company focuses on targeting dysregulated transcription factors and oncogenic signaling pathways. Its lead candidate, entospletinib, is a selective inhibitor of spleen tyrosine kinase aimed at treating acute myeloid leukemia. Additionally, Kronos Bio is developing KB-0742, an orally bioavailable inhibitor of cyclin-dependent kinase 9, intended for MYC-amplified solid tumors. By leveraging advanced technologies such as high-throughput small-molecule microarrays and targeted protein degradation, Kronos Bio aims to identify effective compounds that can modulate historically undruggable cancer targets, ultimately striving to improve patient outcomes through precision medicine.

Attenua

Series A in 2018
Attenua, Inc. is a biotechnology company based in San Mateo, California, founded in 2015. The company focuses on developing non-narcotic medicines specifically aimed at treating chronic cough and other chronic respiratory disorders. Recognizing the unmet needs in therapeutic areas often overlooked by larger pharmaceutical companies, Attenua seeks to uncover small molecule drugs that could significantly benefit patients. The team comprises experienced scientists and former advisors from major pharmaceutical firms, bringing extensive expertise in drug development. By prioritizing the discovery of innovative therapies, Attenua aims to improve the quality of life for individuals suffering from debilitating chronic conditions.

Prevail Therapeutics

Series A in 2018
Prevail Therapeutics Inc. is a biotechnology company headquartered in New York, specializing in the development and commercialization of gene therapies targeting neurodegenerative diseases. Founded in 2017, the company focuses on adeno-associated virus (AAV)-based therapies, with its lead candidate, PR001, currently undergoing Phase I/II clinical trials for Parkinson's disease associated with GBA1 mutations and neuronopathic Gaucher disease. Additionally, Prevail is advancing PR006 for frontotemporal dementia linked to GRN mutations and PR004 for various synucleinopathies. The company's mission is to provide disease-modifying treatments for patients suffering from these challenging conditions.

Senti Bio

Series A in 2018
Senti Biosciences is a clinical-stage biotechnology company specializing in synthetic biology and gene circuit engineering for therapeutic purposes. The company employs its Gene Circuits platform to develop innovative therapies that enhance precision in targeting cancer cells while avoiding damage to healthy cells. Senti Bio's approach involves the use of allogeneic chimeric antigen receptor natural killer (CAR-NK) cells that incorporate its gene circuit technologies, aimed at addressing various oncology indications. Among its product candidates are SENTI-202, a Logic Gated off-the-shelf CAR-NK cell therapy designed to selectively eliminate cancer cells without harming healthy bone marrow, and SENTI-301A, which targets hepatocellular carcinoma. Senti Biosciences aims to provide effective treatment options for difficult-to-treat diseases through advanced cell and gene therapies.

ESSA Pharma

Post in 2018
ESSA Pharma Inc. is a clinical-stage pharmaceutical company based in Vancouver, Canada, specializing in the development of innovative therapies for prostate cancer. Founded in 2009, the company is currently focusing on EPI-7386, an oral drug candidate undergoing Phase I clinical trials aimed at treating patients with metastatic castration-resistant prostate cancer. ESSA's approach targets the N-terminal domain of the androgen receptor, a critical component for the growth and survival of most prostate cancer cells. By selectively blocking this domain, ESSA aims to advance the next generation of hormone therapies for patients battling advanced prostate cancer.

Gossamer Bio

Series A in 2018
Gossamer Bio is a clinical-stage biopharmaceutical company based in San Diego that focuses on the discovery and development of innovative therapeutic products for unmet medical needs. Founded by former executives from Receptos, the company aims to leverage a strong in-licensing strategy and a team with extensive experience in immunology, inflammation, fibrosis, and oncology. Gossamer Bio's pipeline includes several promising candidates: Seralutinib, which targets pulmonary arterial hypertension; GB004, aimed at treating inflammatory bowel diseases such as ulcerative colitis and Crohn's disease; GB1275, designed for various oncology indications; and GB001, intended for moderate-to-severe eosinophilic asthma. Through these efforts, Gossamer Bio seeks to improve patient outcomes in critical therapeutic areas.

Translate Bio

Series C in 2017
Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

ObsEva

Post in 2017
ObsEva SA is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, dedicated to developing innovative therapeutics for women's reproductive health and pregnancy. Founded in 2012 by Ernest Loumaye and André Chollet, the company focuses on addressing serious conditions such as endometriosis, heavy menstrual bleeding, and preterm labor. Its key products include Linzagolix, an oral gonadotropin-releasing hormone receptor antagonist aimed at treating pain from endometriosis and uterine fibroids, and OBE022, a selective prostaglandin F2α receptor antagonist designed for once-daily treatment of preterm labor. Additionally, ObsEva is advancing Nolasiban, an oral oxytocin receptor antagonist intended to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization. The company operates primarily in Switzerland and is committed to improving outcomes for women facing reproductive health challenges.

Visterra

Series C in 2017
Visterra, Inc. is a clinical-stage biopharmaceutical company focused on developing precision antibody-based treatments for difficult-to-treat diseases, particularly infectious diseases. Utilizing its Hierotope platform, Visterra designs monoclonal antibodies such as VIS410, aimed at treating hospitalized patients with influenza A, and VIS513 for Dengue fever. The company is also advancing VIS705, an antibody-drug conjugate for Pseudomonas aeruginosa infections, and VIS649, which targets Immunoglobulin A Nephropathy (IgAN). Founded in 2007 and based in Waltham, Massachusetts, Visterra was previously known as Parasol Therapeutics, Inc. The company operates as a subsidiary of Otsuka America, Inc. and emphasizes innovative therapeutic solutions to address significant unmet medical needs.

Replimune

Series B in 2017
Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Immunic Therapeutics

Series A in 2017
Immunic Therapeutics is a clinical-stage biopharmaceutical company focused on developing selective oral immunology therapies to treat chronic inflammatory and autoimmune diseases. The company's pipeline includes three small molecule products. The lead program, IMU-838, is a selective immune modulator that blocks the enzyme DHODH, inhibiting the metabolism of activated immune cells and exhibiting antiviral effects. It is being developed for multiple sclerosis, ulcerative colitis, Crohn's disease, and primary sclerosing cholangitis. IMU-935, a selective inverse agonist of the transcription factor RORγt, targets psoriasis, castration-resistant prostate cancer, and Guillain-Barré syndrome. Additionally, IMU-856 aims to restore intestinal barrier function for diseases involving bowel barrier dysfunction.

Kezar Life Sciences

Series B in 2017
Kezar Life Sciences, Inc. is a clinical-stage biotechnology company specializing in the discovery and development of small molecule therapeutics aimed at addressing unmet medical needs in autoimmunity and cancer. The company's lead candidate, KZR-616, is a selective immunoproteasome inhibitor currently undergoing Phase 2 clinical trials for various autoimmune conditions, including lupus nephritis and autoimmune hemolytic anemia, as well as Phase 1b/2 trials in systemic lupus erythematosus. In addition to KZR-616, the company is developing KZR-TBD, which targets both oncology and autoimmune disorders. Founded in 2015 and based in South San Francisco, California, Kezar Life Sciences leverages insights from protein homeostasis to advance its drug discovery efforts.

Trevi Therapeutics

Series C in 2017
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in New Haven, Connecticut, dedicated to developing and commercializing nalbuphine ER, an oral extended-release formulation. The company is focused on treating serious neurologically mediated conditions, specifically chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in individuals with Parkinson's disease. Trevi is currently conducting a Phase 2b/3 clinical trial, known as the PRISM trial, for nalbuphine ER, targeting severe pruritus associated with prurigo nodularis. The conditions being addressed share similar underlying mechanisms that involve opioid receptors in both the central and peripheral nervous systems. Founded in 2011, Trevi Therapeutics aims to provide innovative treatment options for patients suffering from these challenging health issues.

Anaconda Biomed

Series A in 2017
Anaconda BioMed is a medical technology company based in Barcelona, Spain, founded in 2015 by Dr. Ofir Arad and Dr. Marc Ribó. The company specializes in developing advanced healthcare devices, particularly focused on neuro-thrombectomy systems for the treatment of acute ischemic stroke (AIS). Its flagship product, the ANCD BRAIN™, is a third-generation stented aspiration thrombectomy system that comprises a delivery catheter, a funnel-shaped aspiration catheter, and a stent retriever. This innovative system is designed to conform to the artery and effectively arrest blood flow, facilitating the full extraction of thrombus without fragmentation. Anaconda BioMed aims to provide patients with immediate treatment options for stroke, significantly reducing the risk of fatality associated with this critical medical condition.

Sienna Biopharmaceuticals

Series B in 2017
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that specializes in the development of innovative therapies for dermatological conditions. The company focuses on immunology and inflammation, targeting specific pathways in the skin. Its lead product candidates include SNA-120, a first-in-class inhibitor currently undergoing Phase IIb clinical trials for psoriasis and associated itching, and SNA-125, a dual Janus kinase 3 inhibitor in Phase I/II trials aimed at treating atopic dermatitis and psoriasis. Additionally, Sienna is developing SNA-001, a topical silver particle suspension in pivotal trials for acne treatment and the reduction of light-pigmented hair. Founded in 2010 and headquartered in Westlake Village, California, Sienna Biopharmaceuticals has experienced significant operational challenges, filing for Chapter 11 bankruptcy in 2019, which was later converted to Chapter 7. The company, previously known as Sienna Labs, Inc., rebranded in February 2016 to better reflect its focus on dermatology and aesthetics.

Translate Bio

Series C in 2017
Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.

Morphic Therapeutic

Series A in 2016
Morphic Therapeutic is a biotechnology company focused on developing oral integrin therapies aimed at treating serious chronic diseases such as autoimmune disorders, cardiovascular conditions, metabolic diseases, fibrosis, and cancer. The company specializes in creating small molecule inhibitors that target various integrins. By leveraging insights into integrin biology, Morphic Therapeutic is building a pipeline of innovative therapeutics designed to address a range of immunological, fibrotic, neoplastic, and vascular diseases, thereby offering potential new treatment options for patients with significant unmet medical needs.

etherna immunotherapies

Series A in 2016
eTheRNA immunotherapies NV specializes in the development of mRNA-based immunotherapies that harness the key role of dendritic cells in the immune system. The company focuses on treating melanoma, triple-negative breast cancer, and infectious diseases through its innovative TriMix technology, which enhances the immune response. Founded in 2013 and headquartered in Niel, Belgium, eTheRNA collaborates strategically with China Grand Pharmaceutical and Healthcare Holdings Limited to advance its research and development efforts. The company aims to lead in nucleic acid-based medicine, enabling partners to create new therapeutic options and improve patient outcomes.

Replimune

Series A in 2015
Replimune Group is a biotechnology company focused on developing oncolytic immune-gene therapies for cancer treatment. Utilizing its proprietary Immulytic platform, Replimune aims to create product candidates that activate the immune system against tumors. The company's lead candidate, RP1, is a modified herpes simplex virus currently undergoing Phase I/II clinical trials for various solid tumors and Phase II trials specifically for cutaneous squamous cell carcinoma. Additionally, Replimune is developing RP2, which targets CTLA-4 to enhance immune response, and RP3, designed to express immune-activating proteins that stimulate T cells. Founded in 2015 and based in Woburn, Massachusetts, Replimune seeks to advance its therapies through clinical trials and explore combinations with other immuno-oncology treatments to enhance efficacy.

Telesta Therapeutics

Venture Round in 2015
Telesta Therapeutics is a Canadian biopharmaceutical company dedicated to the development, manufacturing, and commercialization of innovative therapeutics aimed at addressing significant unmet medical needs, primarily in oncology. The company is focused on creating novel medicines that can transform the treatment landscape for serious diseases, including cancer and immune disorders. Its lead product, MCNA, has successfully completed a Phase III pivotal study for patients with non-muscle invasive bladder cancer who have not responded to initial treatment with bacillus Calmette-Guérin (BCG). Telesta submitted a Biologics Licensing Application to the U.S. FDA in June 2015 and aims to provide MCNA to patients and healthcare providers pending approval. Ultimately, the company seeks to enhance the quality of life and extend survival for individuals affected by bladder cancer, one of the most prevalent cancers today.

Kuros Biosciences

Post in 2015
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Editas Medicine

Series B in 2015
Editas Medicine is a clinical-stage biotechnology company based in Cambridge, Massachusetts, with an additional site in Boulder, Colorado. Founded in 2013, the company focuses on the discovery and development of genome editing therapeutics, primarily utilizing its proprietary CRISPR/Cas9 technology. This innovative platform enables precise molecular modifications at the genetic level, with the aim of treating a wide array of serious diseases by addressing their underlying causes. Editas Medicine has established a strong intellectual property portfolio, which includes numerous patents related to foundational genome editing technologies and advancements that facilitate the translation of research into viable human therapeutics. The company's mission is to pioneer transformative genomic medicines that can significantly improve patient outcomes across various genetic disorders.

Translate Bio

Series B in 2015
Translate Bio, Inc. is a clinical-stage biotechnology company focused on developing messenger RNA (mRNA) therapeutics aimed at addressing diseases linked to protein or gene dysfunction. Founded in 2011 and headquartered in Lexington, Massachusetts, the company is advancing its lead candidates, MRT5005 and MRT5201. MRT5005 is currently undergoing Phase I/II clinical trials for the treatment of cystic fibrosis, while MRT5201 is being developed for ornithine transcarbamylase deficiency. Translate Bio was previously known as RaNA Therapeutics, Inc. before rebranding in June 2017. The company specializes in innovative therapies for rare diseases, leveraging the potential of RNA-based medicine.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.